Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 9,635 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 9,635 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $25.03, for a total value of $241,164.05. Following the transaction, the director owned 25,545 shares of the company’s stock, valued at approximately $639,391.35. This trade represents a 27.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Enliven Therapeutics Trading Down 3.7%

Shares of NASDAQ:ELVN opened at $25.03 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -13.60 and a beta of 0.41. The company has a fifty day simple moving average of $19.17 and a 200 day simple moving average of $19.97. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commodore Capital LP raised its position in shares of Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares during the period. Polar Capital Holdings Plc grew its stake in Enliven Therapeutics by 1.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after buying an additional 44,713 shares during the last quarter. Vanguard Group Inc. increased its position in Enliven Therapeutics by 5.9% in the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares during the period. Vestal Point Capital LP increased its position in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after buying an additional 910,000 shares during the period. Finally, Duquesne Family Office LLC lifted its stake in Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after buying an additional 484,405 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELVN has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Enliven Therapeutics News Roundup

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: MSN published a piece noting Enliven has rising relative price strength, a technical signal that can attract momentum traders and institutional interest. Article Title
• Neutral Sentiment: Short-interest data reported an anomalous reading (zero shares reported as of Jan 12), producing no clear bearish signal; the metric is effectively neutral/uncertain and unlikely to explain today’s move on its own.
• Negative Sentiment: Chief insider selling: CEO/insider Joseph P. Lyssikatos completed multiple sales (41,302 shares at ~$24.05 and 91,198 shares at ~$27.22), generating roughly $3.47M in proceeds and reducing his stake by double-digit percentages in those transactions — a notable supply event that can pressure the share price. SEC Filing
• Negative Sentiment: Director sales: Richard A. Heyman sold 9,635 shares (avg $25.03) and 4,285 shares (avg $25.00) across Jan 8–9, totaling ~13,920 shares and ≈$348k — further insider selling that likely added downward pressure. SEC Filing

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.